Aristea begins patient dosing in phase 2a trial of RIST4721 in hidradenitis suppurativa

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company, announced the dosing of the first patient in its phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of hidradenitis suppurativa (HS), a chronic and progressive inflammatory dermatological condition. "We are delighted to continue expanding the development of RIST4721 into additional inflammatory conditions beyond our lead program in palmoplantar pustulosis," stated James M. Mackay, Ph.D., president and CEO of Aristea. "There is a significant unmet medical need for treatments for HS patients and we are excited to have commenced this important clinical trial with RIST4721 in collaboration with our partner Pfizer." HS is a chronic and progressive inflammatory dermatological condition that causes skin nodules, abscesses, and scarring, resulting in significant pain. The disease usually affects skin folds where the skin rubs together, including the armpits, groin, buttocks, and breasts, and it can be a serious impediment to quality of life. HS is estimated to affect between <1% and 4% of the population in the United States and Europe. Antibiotics, steroids, retinoids, over the counter (OTC) pain medication, hormonal therapies, and immune-modulating biologics are used to control symptoms but have limited success. RIST4721-221 is a randomized, double-blind, placebo-controlled, phase 2a study to evaluate the safety and efficacy of RIST4721 in subjects with hidradenitis suppurativa. This trial is currently recruiting patients within North America (clinicaltrials.gov NCT05348681). "This phase 2a study represents the second disease under investigation for our CXCR2 antagonist, RIST4721 and its initiation brings us one step closer to potentially developing a treatment for HS," commented Dr. Nihar Bhakta, Aristea's chief medical officer. Aristea has phase 2 studies in development for RIST4721 in three additional neutrophil-mediated diseases: familial Mediterranean fever, Behcet's disease, and palmoplantar pustulosis. Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!